NASDAQ$GOSS
Gossamer Bio Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Gossamer Bio's financial performance and business progress were detailed for Q3 2024.
Gossamer Bio reported $327 million in cash, cash equivalents and marketable securities as of September 30, 2024. Revenue from contracts with collaborators was $9.5 million. R&D expenses were $34.9 million, and G&A expenses were $8.5 million. The net loss for the quarter was $30.8 million, or $0.14 per share.
- Cash, cash equivalents, and marketable securities totaled $327.0 million as of September 30, 2024.
- Revenue from contracts with collaborators was $9.5 million for the quarter ended September 30, 2024.
- R&D expenses were $34.9 million for the quarter ended September 30, 2024.
- Net loss for the quarter ended September 30, 2024, was $30.8 million, or $0.14 basic net loss per share.
Headline financials
Revenue & EPS history
Gossamer Bio · Revenue · Quarterly
$9.48M
Revenue by segment
Gossamer Bio · $17M total across 1 segment · Q1 2026
- Collaborators$17M—100.0%
Forward guidance
Gossamer Bio anticipates a pivotal year in 2025 with Phase 3 PROSERA Study results in PAH and the commencement of a Phase 3 study in PH-ILD.
Tailwinds
- Expect 2025 to be an exceptionally important year.
- Anticipate Phase 3 PROSERA Study results in PAH.
- Commence PH-ILD Phase 3 study.
- Completing PROSERA Study enrollment.
- Designing the registrational Phase 3 PH-ILD clinical trial.
Headwinds
- Potential delays in the commencement, enrollment and completion of clinical trials
- Disruption to operations from the COVID-19 pandemic, including clinical trial delays
- Dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing
- Unexpected adverse side effects or inadequate efficacy of seralutinib that may limit their development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims
- Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
13 / 30 earnings
Positive
+15.2%
Q4 2022
Best reaction
-15.6%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -34.9% | -50.9% | |
| Q4 2025 | -10.8% | -21.0% | -5.5% | |
| Q3 2025 | +2.2% | +16.9% | +44.2% | |
| Q2 2025 | -8.5% | -18.9% | +15.7% | |
| Q1 2025 | +1.0% | +9.5% | +18.1% | |
| Q4 2024 | +0.0% | +6.0% | -38.4% | |
| Q3 2024 | -0.9% | -4.4% | -15.1% | |
| Q2 2024 | +4.3% | +7.5% | +12.5% | |
| Q1 2024 | -3.2% | -5.0% | -23.2% | |
| Q4 2023 | +4.1% | -4.8% | -26.2% | |
| Q3 2023 | -12.0% | +4.7% | +73.1% | |
| Q2 2023 | -7.0% | -9.3% | -24.7% | |
| Q1 2023 | +3.7% | -11.8% | -7.4% | |
| Q4 2022 | +15.2% | +5.7% | -0.5% | |
| Q3 2022 | -0.8% | -4.2% | -14.9% | |
| Q2 2022 | +4.6% | +6.5% | +13.7% | |
| Q1 2022 | +12.5% | +34.2% | +9.5% | |
| Q4 2021 | +3.7% | +1.0% | -2.8% | |
| Q3 2021 | -1.4% | -9.1% | -16.6% | |
| Q2 2021 | -0.8% | +9.5% | +18.9% | |
| Q1 2021 | -0.7% | -0.7% | +1.7% | |
| Q4 2020 | -9.4% | -5.5% | -11.6% | |
| Q3 2020 | -0.9% | -1.3% | +4.2% | |
| Q2 2020 | +5.1% | +2.4% | -1.1% | |
| Q1 2020 | -15.6% | -11.5% | -27.8% | |
| Q4 2019 | +5.5% | +5.7% | +40.0% | |
| Q3 2019 | -4.3% | -1.2% | +12.4% | |
| Q2 2019 | -2.5% | +3.2% | +2.6% | |
| Q1 2019 | +1.3% | +3.7% | -3.9% | |
| Q4 2018 | -4.9% | -10.8% | -30.1% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro